Type: Securities Fraud case filed

According to the Complaint, the Company made false and misleading statements to the market. Evolv overstated the efficacy of its products. The Company’s products and their inability to effectively detect guns and knives led to an increase of undetected weapons entering sensitive locations such as schools. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Evolv, investors suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. Shoals failed to deliver electrical balance of system (“EBOS”) products at a high level of reliability and quality. The Company was aware that a large number of its EBOS systems used in solar fields were defective. The Company incurred costs of between $60 million and $185 million to remediate its defective products. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Shoals, investors suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. Chemours’ management team manipulated targets for free cash flow to maximize executive compensation under its Annual Incentive Plans and Long-Term Incentive Plans. The Company failed to maintain appropriate controls over financial reporting. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Chemours, investors suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. The Company’s purported visibility into medical costs and utilization costs was touted by agilon’s management team. The Company failed to disclose the increased medical costs it had incurred due to higher utilization by Healthcare MA patients. The Company falsely stated its accounting reserves for higher utilization were adequate for its needs. The Company issued overly optimistic guidance for financial performance. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about agilon, investors suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. SSR Mining overstated its commitment to safety and misrepresented the efficacy of its safety measures. The Company engaged in unsafe mining practices that increased the chances of a mining disaster. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about SSR Mining, investors suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. Innoviz overstated the benefits of its alleged contracts and partnerships with automotive companies. The Company was unlikely to achieve the profitability it touted to investors. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Innoviz, investors suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. Anavex provided investors with a materially inaccurate portrayal of its research program and the likelihood of product candidate blarcamesine succeeding in the “Excellence” Phase II/Phase III trial. The Company then announced the usage of the “MMRM” statistical methodology in the Excellence trial to analyze the study’s data, which ultimately failed to achieve statistical significance. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Anavex, investors suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. iRobot’s merger with Amazon (“the Merger”) would give Amazon a dominant position in robot vacuum cleaners (“RVCs”), making it unlikely that American and European authorities would approve it. The Company failed to complete adequate due diligence on the Merger and ignored regulatory risks. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about iRobot, investors suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. Lyft issued a press release detailing its fourth quarter operating results on February 13, 2024. The Company stated it expected “adjusted EBITDA margin expansion … of approximately 500 basis points year-over-year.” In fact, the Company expected a 50 basis point margin expansion. The Company corrected its error 17 minutes into its earnings call, causing shares to fall sharply. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Lyft, investors suffered damages.

According to the Complaint, the Company made false and misleading statements to the market. The lead clinical product candidate developed by Ventyx, VTX958, was less effective in the treatment of psoriasis than it portrayed to investors. The Company overstated the commercial prospects of VTX958. The Company misrepresented its ability to develop and commercialize drug candidates. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Ventyx, investors suffered damages.